Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 47 | 6,887 | 44% |
| 2020 | 46 | 6,565 | 46% |
| 2021 | 40 | 6,321 | 49% |
| 2022 | 39 | 6,481 | 51% |
| 2023 | 38 | 5,760 | 53% |
| 2024 | 38 | 4,850 | 54% |
| 2025 from claims | – | 4,255 3,905–4,501 | 55% |
| 2026 forecast | – | 4,328 3,808–4,994 | 55% |
| 2027 forecast | – | 4,386 3,749–5,226 | 56% |
| 2028 forecast | – | 4,444 3,708–5,441 | 56% |
| 2029 forecast | – | 4,502 3,677–5,646 | 57% |
| 2030 forecast | – | 4,561 3,654–5,845 | 57% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 65% of the cases CMS names in Arizona; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 17% inpatient hospital, 9% hospital outpatient, 17% surgery center, 57% office. The share outside the hospital has moved −2 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 147 | 24,119−1.9%/yr | −1.9%/yr | 6.9 | 85% | 23,300 in 2030−0.6%/yr |
| Washington | 15 | 2,037−9%/yr | −9%/yr | 2.5 | 14% | 2,490 in 2030+3.4%/yr |
| Oregon | 14 | 1,434−4.5%/yr | −4.5%/yr | 3.3 | 63% | 1,890 in 2030+4.7%/yr |
| Nevada | 9 | 1,215−6.2%/yr | −6.2%/yr | 4.0 | 73% | 1,790 in 2030+6.7%/yr |
| Colorado | 6 | 1,107−8.7%/yr | −8.7%/yr | 2.2 | 43% | 1,830 in 2030+8.7%/yr |
| Utah | 6 | 843+4%/yr | +4%/yr | 3.7 | 48% | 190 in 2030−22%/yr |
| Idaho | 5 | 646+5.1%/yr | +5.1%/yr | 3.0 | 47% | 4,230 in 2030+37%/yr |
| New Mexico | 3 | 559−14%/yr | −14%/yr | 2.3 | 9% | 460 in 2030−3.1%/yr |
| Hawaii | 2 | 363+2.9%/yr | +2.9%/yr | 2.7 | 91% | 690 in 2030+11%/yr |
| Montana | 5 | 334−8.2%/yr | −8.2%/yr | 1.7 | 0% | 370 in 2030+1.5%/yr |
| Alaska | 4 | 237+4%/yr | +4%/yr | 2.0 | 0% | 380 in 2030+8.3%/yr |
| Wyoming | 1 | 176+0.3%/yr | +0.3%/yr | 1.6 | 0% | 200 in 2030+2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 94 | 10,087−0.8%/yr | −0.8%/yr | 13.02.6× | 100% | 10,200 in 2030+0.2%/yr |
| Dialysis access | 33 | 3,680−7.6%/yr | −7.6%/yr | 5.21.1× | 88% | 4,140 in 2030+2%/yr |
| Thrombectomy, IVC filters & venous stents | 11 | 1,180+4.1%/yr | +4.1%/yr | 1.61.4× | 19% | 1,490 in 2030+3.9%/yr |
| Carotid revascularization | 21 | 884−3%/yr | −3%/yr | 1.21.5× | 0% | 1,070 in 2030+3.3%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 322−6.9%/yr | −6.9%/yr | 0.41.4× | 0% | 370 in 2030+2.5%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Medtronic leads with 72% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 10 companies reported engagement with Arizona’s surgeons worth $33K in consulting, speaking, meals and travel tied to these products, about $866 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.